文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症心脑血管急症

危重患儿的不良结局与死亡:病理生理及潜在治疗方案的定性患者层面分析

Morbidity and Mortality in Critically Ill Children. II. A Qualitative Patient-Level Analysis of Pathophysiologies and Potential Therapeutic Solutions.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论PICU中导致新发功能障碍或死亡的最常见病理生理为低心排/心脏骤停所致底物输送障碍、炎症相关器官衰竭及中枢神经系统创伤。

该研究对8家儿童医院PICU中随机选取的292例出院时新发功能障碍或死亡的危重患儿进行结构化病历回顾,由重症医师对病理生理过程及所需治疗进展做出结论并进行定性内容分析。新发功能障碍采用功能状态量表评估,定义为单一维度较病前基线恶化≥2分。292例中175例(59.9%)新发功能障碍、117例(40.1%)死亡;最常见病理生理为底物输送障碍(n=158,54.1%),表现为低心排或心脏骤停所致的整体或区域缺氧/缺血;其次为炎症(n=104,35.6%)和直接组织损伤(n=64,21.9%)。慢性基础病常被记录为不良结局的促进因素(n=156,53.4%)。最常被提出的所需治疗进展为药物治疗(n=149,51.0%),包括化疗、正性肌力药、血管活性药和镇静药。

要点

  • 292例危重患儿中175例(59.9%)新发功能障碍、117例(40.1%)死亡;新发功能障碍定义为功能状态量表单一维度较病前基线恶化≥2分。
  • 最常见病理生理为底物输送障碍(n=158,54.1%),表现为低心排或心脏骤停所致的整体或区域缺氧/缺血。
  • 炎症相关病理生理占35.6%(n=104),与脓毒症、呼吸衰竭、急性呼吸窘迫综合征或多器官功能障碍相关。
  • 直接组织损伤占21.9%(n=64),包括脑和脊髓创伤;慢性基础病常被记录为不良结局的促进因素(n=156,53.4%)。
  • 最常被提出的所需治疗进展为药物治疗(n=149,51.0%),包括化疗、正性肌力药、血管活性药和镇静药;细胞再生(n=115,39.4%)主要用于神经元损伤。

适用人群与场景

  • 8家隶属于尤妮斯·肯尼迪·施莱佛国家儿童健康与人类发展研究所协作儿科重症监护研究网络的儿童医院PICU中,随机选取的出院时新发功能障碍或死亡的危重患儿。
  • 新发功能障碍采用功能状态量表评估,定义为单一维度较病前基线恶化≥2分。

诊断标准与关键阈值

  • 新发功能障碍:功能状态量表单一维度较病前基线恶化≥2分。

研究设计与关键结果

  • 研究类型为对重症医师结构化病历回顾结论的定性内容分析;共纳入292例危重患儿,来自8家儿童医院。
  • 292例中175例(59.9%)新发功能障碍,117例(40.1%)死亡。
  • 最常见病理生理为底物输送障碍(n=158,54.1%),表现为低心排或心脏骤停所致的整体或区域缺氧/缺血。
  • 炎症相关病理生理(n=104,35.6%)与脓毒症、呼吸衰竭、急性呼吸窘迫综合征或多器官功能障碍相关。
  • 直接组织损伤(n=64,21.9%)包括脑和脊髓创伤;慢性基础病常被记录为不良结局的促进因素(n=156,53.4%)。
  • 最常被提出的所需治疗进展为药物治疗(n=149,51.0%),包括化疗、正性肌力药、血管活性药和镇静药。
  • 其他常被提出的治疗包括细胞再生(n=115,39.4%),主要用于神经元损伤的治疗;以及改善免疫和炎症调节(n=79,27.1%)。

证据类型、等级与局限

  • 证据类型:定性内容分析(基于结构化病历回顾的重症医师结论)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,低心排和心脏骤停、炎症相关器官衰竭及中枢神经系统创伤是PICU中最常见导致不良结局与死亡的病理生理,聚焦于更好理解和治疗这些情况的研究议程可能对患者结局产生直接影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe at the individual patient level the pathophysiologic processes contributing to morbidity and mortality in PICUs and therapeutic additions and advances that could potentially prevent or reduce morbidity and mortality.

DESIGN: Qualitative content analysis of intensivists' conclusions on pathophysiologic processes and needed therapeutic advances formulated by structured medical record review.

SETTING: Eight children's hospitals affiliated with the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network.

PATIENTS: A randomly selected cohort of critically ill children with a new functional morbidity or mortality at hospital discharge. New morbidity was assessed using the Functional Status Scale and defined as worsening by two or more points in a single domain from preillness baseline.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 292 children, 175 (59.9%) had a new morbidity and 117 (40.1%) died. The most common pathophysiology was impaired substrate delivery (n = 158, 54.1%) manifesting as global or regional hypoxia or ischemia due to low cardiac output or cardiac arrest. Other frequent pathophysiologies were inflammation (n = 104, 35.6%) related to sepsis, respiratory failure, acute respiratory distress syndrome, or multiple organ dysfunction; and direct tissue injury (n = 64, 21.9%) including brain and spinal cord trauma. Chronic conditions were often noted (n = 156, 53.4%) as contributing to adverse outcomes. Drug therapies (n = 149, 51.0%) including chemotherapy, inotropes, vasoactive agents, and sedatives were the most frequently proposed needed therapeutic advances. Other frequently proposed therapies included cell regeneration (n = 115, 39.4%) mainly for treatment of neuronal injury, and improved immune and inflammatory modulation (n = 79, 27.1%).

CONCLUSIONS: Low cardiac output and cardiac arrest, inflammation-related organ failures, and CNS trauma were the most common pathophysiologies leading to morbidity and mortality in PICUs. A research agenda focused on better understanding and treatment of these conditions may have high potential to directly impact patient outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Meert KL, Banks R, Holubkov R, et al. Morbidity and Mortality in Critically Ill Children. II. A Qualitative Patient-Level Analysis of Pathophysiologies and Potential Therapeutic Solutions. Crit Care Med. 2020. PMID: 32301845. doi:10.1097/CCM.0000000000004332

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。